---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Special populations"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Special populations. Topics: Phase 3 trial population: age, cardiovascular, urinary, ocular, and pregnancy criteria; Older men: age limits in the earlier trials because of urinary risk; Subgroups by sex, weight class, and baseline severity in SynAIRgy; Reduced CYP2D6 activity: proposed contribution to variability in tolerability; 8 further topics. 12 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/special-populations"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Phase 3 trial population: age, cardiovascular, urinary, ocular, and pregnancy criteria

> “The targeted study population is adults (≥18 years old, no upper age limit) with OSA of any severity defined as an AHI4>5 events/h (hypopneas scored when associated with 4% desaturation) with ≤25% central or mixed apneas (as proportion of total apneas and hypopneas), and PLM arousal index ≤15 events/h on the screening PSG.”
> “Potential participants with clinically significant or medically uncontrolled cardiovascular disease such as unstable atrial fibrillation, untreated or unstable coronary artery disease, heart failure, cerebrovascular events and resting heart rate >100 beats per min or blood pressure greater than 145/90 mmHg were excluded.”
> “Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying”
> “Narrow angle glaucoma”
> “Women who are pregnant or nursing”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.8-2"></a>

### Older men: age limits in the earlier trials because of urinary risk

> “The trials reported above excluded male patients >65 due to concerns for higher risk of urinary problems with ato-oxy or AD109 in the older male population. Women over 65 years of age were allowed in the trial without any reported safety concerns.”

Source: [Taranto-Montemurro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12713960/)

> “Age requirement was 18–65 years for men and 18–75 for women.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.8-3"></a>

### Subgroups by sex, weight class, and baseline severity in SynAIRgy

> “In supportive analyses, AD109 improved AHI across diverse subgroups, such as those defined by sex, weight class, and baseline OSA severity (mild, moderate, and severe), supporting the generalizability of study findings to a broad spectrum of patients with OSA.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.8-4"></a>

### Reduced CYP2D6 activity: proposed contribution to variability in tolerability

> “Tolerability may also have been influenced by interindividual variability in atomoxetine metabolism related to cytochrome P450 2D6 (CYP2D6) status. Individuals with reduced CYP2D6 activity may have higher systemic exposure to atomoxetine, which could contribute to variability in adverse events such as insomnia as well as in heart rate and blood pressure responses.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.8-5"></a>

### Atomoxetine label: CYP2D6 poor metabolizers

> “Atomoxetine plasma concentrations were higher in CYP2D6 poor metabolizers which may increase the risk of STRATTERA-related adverse reactions.”
> “The prevalence of CYP2D6 poor metabolizers is approximately 7% in White populations, 2% in Asian populations, and 2% in Black or African American populations.”
> “Consider genetic testing to determine the patient’s CYP2D6 metabolizer status.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-6"></a>

### Atomoxetine label: hepatic impairment

> “The recommended dosage in patients with moderate or severe hepatic impairment is lower than in patients with normal hepatic function”
> “Moderate HI (Child-Pugh Class B), the recommended initial and target STRATTERA dosage is 50% of the recommended dosage in patients with normal hepatic function”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

### Atomoxetine label: renal impairment

> “Patients with severe renal impairment (end stage renal disease requiring hemodialysis) had higher systemic atomoxetine exposure (about a 65% increase) than patients with normal renal function (CrCl ≥ 90 ml/minute) in other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate), but there was no difference when exposure was corrected for mg/kg dose. Thus, the differences in exposure were not clinically significant.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-8"></a>

### Atomoxetine label: geriatric use

> “The safety, efficacy and pharmacokinetics of STRATTERA in geriatric patients have not been evaluated. Clinical studies of STRATTERA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-9"></a>

### Atomoxetine label: pregnancy and lactation

> “Available published studies with STRATTERA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Some animal reproduction studies of atomoxetine had adverse developmental outcomes.”
> “There are no data on the presence of atomoxetine or its metabolite in human milk, the effects on the breastfed child, or the effects on milk production.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-10"></a>

### Oxybutynin label: geriatric use

> “The rate and severity of anticholinergic effects reported by patients less than 65 years old and those 65 years and older were similar. The pharmacokinetics of DITROPAN XL® were similar in all patients studied (up to 78 years of age).”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.8-11"></a>

### Oxybutynin label: renal and hepatic impairment

> “There were no studies conducted with DITROPAN XL® in patients with renal impairment.”
> “There were no studies conducted with DITROPAN XL® in patients with hepatic impairment.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.8-12"></a>

### Oxybutynin label: pregnancy and lactation

> “There are no adequate data on DITROPAN XL® use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
> “There are no data on the presence of oxybutynin in human milk, the effects on the breastfed infant, or the effects of DITROPAN XL® on milk production.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
